Compounded Topical Finasteride Formulas: Concentrations and Carriers Explained

The compounded topical you receive is defined by three things: the active concentration, the carrier vehicle, and the compounding pharmacy's quality. All three matter — and they are not all disclosed upfront.

Compounded topical finasteride is not a single product. It is a category of preparations defined by several variables that significantly affect both local efficacy and systemic exposure. Understanding what those variables are and how they interact is useful before choosing a platform or formulation.

Concentration: the active ingredient dose

Finasteride concentration in compounded topicals typically ranges from 0.1% to 0.25%. The most studied formulation is 0.25% applied once daily — the concentration used in the primary published research showing approximately 20–30% serum DHT suppression and 60–70% scalp DHT suppression in controlled conditions.

Lower concentrations (0.1%) are sometimes used when minimising systemic absorption is the primary goal; the trade-off is potentially reduced scalp DHT suppression. Some platforms use lower concentrations combined with more penetration-enhancing vehicles to compensate. Concentrations above 0.25% are not standard and the evidence for additional benefit is thin.

The carrier vehicle: often more important than concentration

The carrier vehicle is the medium in which finasteride is dissolved or suspended. It determines how much of the drug penetrates the skin to reach the follicle, how much remains in the superficial layers, and how much is absorbed systemically. Two products at the same concentration in different vehicles can produce very different scalp DHT suppression and systemic exposure profiles.

Alcohol-water solutions

The most basic vehicle. Low viscosity, easy to apply, dries quickly. Delivers finasteride to the scalp but with variable penetration depth. Generally lower follicular targeting than purpose-designed vehicles. Most commonly used in early compounded topicals.

Liposomal formulations

Liposomes are lipid vesicles that encapsulate the drug and are designed to fuse with cell membranes, enhancing delivery to the follicle. Liposomal carriers improve follicular penetration relative to simple solutions, which in principle means similar or better scalp DHT suppression with potentially lower systemic absorption. More technically demanding to compound consistently.

Gels and sprays

Different application mechanics but not necessarily different penetration profiles — the penetration is driven by the formulation chemistry, not the application format. Sprays can provide more even distribution across the scalp; gels may provide better contact time. These are practical considerations rather than efficacy differentiators by themselves.

Combination formulas

Topical finasteride is commonly combined with other actives in a single vehicle. The most common combination is finasteride plus minoxidil — delivering both a DHT inhibitor and a follicle-stimulating vasodilator in one application. Some formulations add other actives such as tretinoin or biotin. Combinations reduce the number of daily applications required and may have additive benefit, though head-to-head comparative data for most combinations is limited.

Compounding quality variability

Unlike commercial pharmaceutical products, compounded preparations are not subject to FDA pre-market approval for consistency, potency, or purity. Quality depends on the compounding pharmacy's practices. PCAB accreditation is a voluntary standard that involves third-party inspection and testing. Telehealth platforms working with accredited compounding partners provide a meaningful layer of quality assurance that platforms using unaccredited compounders do not.

If your platform does not readily answer questions about their compounding partner's accreditation, that is worth knowing.